Literature DB >> 12186875

Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha.

Denise A Chan1, Patrick D Sutphin, Nicholas C Denko, Amato J Giaccia.   

Abstract

Stabilization of the hypoxia-inducible factor-1 (HIF-1) protein is essential for its role as a regulator of gene expression under low oxygen conditions. Here, employing a novel hydroxylation-specific antibody, we directly show that proline 564 of HIF-1alpha and proline 531 of HIF-2alpha are hydroxylated under normoxia. Importantly, HIF-1alpha Pro-564 and HIF-2alpha Pro-531 hydroxylation is diminished with the treatment of hypoxia, cobalt chloride, desferrioxamine, or dimethyloxalyglycine, regardless of the E3 ubiquitin ligase activity of the von Hippel-Lindau (VHL) tumor suppressor gene. Furthermore, in VHL-deficient cells, HIF-1alpha Pro-564 and HIF-2alpha Pro-531 had detectable amounts of hydroxylation following transition to hypoxia, indicating that the post-translational modification is not reversible. The introduction of v-Src or RasV12 oncogenes resulted in the stabilization of normoxic HIF-1alpha and the loss of hydroxylated Pro-564, demonstrating that oncogene-induced stabilization of HIF-1alpha is signaled through the inhibition of prolyl hydroxylation. Conversely, a constitutively active Akt oncogene stabilized HIF-1alpha under normoxia independently of prolyl hydroxylation, suggesting an alternative mechanism for HIF-1alpha stabilization. Thus, these results indicate distinct pathways for HIF-1alpha stabilization by different oncogenes. More importantly, these findings link oncogenesis with normoxic HIF-1alpha expression through prolyl hydroxylation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186875     DOI: 10.1074/jbc.M206922200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.

Authors:  Natsuko Suwaki; Elsa Vanhecke; Katelyn M Atkins; Manuela Graf; Katherine Swabey; Paul Huang; Peter Schraml; Holger Moch; Amy Mulick Cassidy; Daniel Brewer; Bissan Al-Lazikani; Paul Workman; Johann De-Bono; Stan B Kaye; James Larkin; Martin E Gore; Charles L Sawyers; Peter Nelson; Tomasz M Beer; Hao Geng; Lina Gao; David Z Qian; Joshi J Alumkal; Gary Thomas; George V Thomas
Journal:  Sci Transl Med       Date:  2011-06-01       Impact factor: 17.956

2.  Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing.

Authors:  Joe G N Garcia; Roberto F Machado; Victor R Gordeuk; Xu Zhang; Wei Zhang; Shwu-Fan Ma; Galina Miasniakova; Adelina Sergueeva; Tatiana Ammosova; Min Xu; Sergei Nekhai; Mehdi Nourai; Michael S Wade; Josef T Prchal
Journal:  Blood Cells Mol Dis       Date:  2013-08-28       Impact factor: 3.039

Review 3.  Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers.

Authors:  Jordan M Thompson; Jaime Landman; Olga V Razorenova
Journal:  Small GTPases       Date:  2017-07-07

Review 4.  The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling.

Authors:  Edurne Berra; Amandine Ginouvès; Jacques Pouysségur
Journal:  EMBO Rep       Date:  2006-01       Impact factor: 8.807

5.  Basal HIF-1α expression levels are not predictive for radiosensitivity of human cancer cell lines.

Authors:  D Schilling; C Bayer; K Emmerich; M Molls; P Vaupel; R M Huber; G Multhoff
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

6.  Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors.

Authors:  Ian F Robey; Anthony D Lien; Sarah J Welsh; Brenda K Baggett; Robert J Gillies
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

Review 7.  Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress.

Authors:  Ambreena Siddiq; Leila R Aminova; Rajiv R Ratan
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

8.  Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.

Authors:  Jordan M Thompson; Alejandro Alvarez; Monika K Singha; Matthew W Pavesic; Quy H Nguyen; Luke J Nelson; David A Fruman; Olga V Razorenova
Journal:  Mol Cancer Ther       Date:  2018-05-02       Impact factor: 6.261

9.  Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5.

Authors:  Lynne Bemis; Denise A Chan; Carla V Finkielstein; Lin Qi; Patrick D Sutphin; Xiaojiang Chen; Kurt Stenmark; Amato J Giaccia; Wayne Zundel
Journal:  Genes Dev       Date:  2004-04-01       Impact factor: 11.361

10.  Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response.

Authors:  Olga Aprelikova; Silvia Pandolfi; Sean Tackett; Mark Ferreira; Konstantin Salnikow; Yvona Ward; John I Risinger; J Carl Barrett; John Niederhuber
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.